Cardiac Involvement in Fabry Disease
Key result
Early diagnosis and targeted therapies limit progressive cardiovascular complications in Fabry disease.
Why the study?
Fabry disease causes cardiac involvement that limits quality of life and is the most common cause of death, with evolving understanding and treatment options requiring updated synthesis.
Population
Patients with Fabry disease
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Supports early diagnosis to avert inflammation-driven fibrosis in Fabry cardiomyopathy; leaves open optimal sequencing of enzyme replacement and chaperone therapies.
Key Points
- To review the pathophysiological mechanisms, diagnostic imaging advancements, and evolving treatment options for cardiac involvement in Fabry disease.
- Synthesized clinical literature on Fabry disease pathophysiology, lysosomal accumulation of globotriasylceramide, and cardiovascular manifestations.
- Evaluated diagnostic and staging imaging modalities alongside therapeutic approaches including enzyme replacement therapy and oral chaperone therapy.
- Accumulation of globotriasylceramide in cardiac tissue leads to left ventricular hypertrophy, myocardial fibrosis, heart failure, and arrhythmias, which constitute the primary cause of death in Fabry disease.
- Advances in cardiac imaging indicate that secondary mechanisms, particularly myocardial inflammation, contribute substantially to cardiomyopathy progression beyond substrate accumulation alone.
- Early initiation of enzyme replacement therapy or newly approved oral chaperone therapies slows disease progression and prevents major adverse cardiovascular events.
Structured PICO
P
Population
Patients with Fabry disease
This review highlights the pathophysiology, imaging advances, and evolving treatment landscape, including enzyme replacement and oral chaperone therapies, for Fabry cardiomyopathy.
Cite This Study
Pieroni et al. (2021) conducted a review in Fabry disease. Fabry disease causes progressive cardiovascular complications, emphasizing the need for early diagnosis and evolving treatments like enzyme replacement and oral chaperone therapy.